Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...

But this same mechanism may increase the risk of rare ... similar warnings as the popularity of Ozempic and other weight-loss drugs has risen. In the U.S. alone, at least 12% of adults have ...

“It’s clearly working on the other mechanisms. We know that for sure.” And regardless of how they work, if weight loss and diabetes drugs can be repurposed to prevent or treat ...

“While further research is needed, liraglutide may work through various mechanisms, such as reducing inflammation ... (Read more on AARP: Side Effects of Weight Loss Drugs.) For older adults, a key ...

Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain ... programme for the drug next year. Cachexia is a complicated metabolic disorder that results in loss of muscle and ...

Americans are split on using weight loss drugs such as Ozempic and Wegovy to treat obesity or weight-related conditions, ...

Moderate-intensity exercise helps regulate appetite and boosts key weight loss hormones, offering benefits similar to weight ...

A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...